GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ImmunityBio Inc (FRA:26CA) » Definitions » Construction In Progress

ImmunityBio (FRA:26CA) Construction In Progress : €77.23 Mil (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is ImmunityBio Construction In Progress?

ImmunityBio's quarterly construction in progress increased from Mar. 2024 (€78.36 Mil) to Jun. 2024 (€79.26 Mil) but then declined from Jun. 2024 (€79.26 Mil) to Sep. 2024 (€77.23 Mil).

ImmunityBio's annual construction in progress increased from Dec. 2021 (€14.67 Mil) to Dec. 2022 (€68.62 Mil) and increased from Dec. 2022 (€68.62 Mil) to Dec. 2023 (€77.43 Mil).


ImmunityBio Construction In Progress Historical Data

The historical data trend for ImmunityBio's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ImmunityBio Construction In Progress Chart

ImmunityBio Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Construction In Progress
- 1.10 14.67 68.62 77.43

ImmunityBio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 80.82 77.43 78.36 79.26 77.23

ImmunityBio Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.


ImmunityBio Business Description

Traded in Other Exchanges
Address
3530 John Hopkins Court, San Diego, CA, USA, 92121
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: United states and Europe. Key revenue is generated from Europe.

ImmunityBio Headlines

No Headlines